DOCSLIB.ORG

A Map of the Alternative Biomedical R&D Landscape

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Map of the Alternative Biomedical R&D Landscape A map of the alternative biomedical R&D landscape ACKNOWLEDGEMENTS We would like to acknowledge all the engaged and active student leaders in UAEM who have supported, participated and activated around the critical global health issue of alternative biomedical R&D, the role of universities and ensuring access to medicines for all. Thanks as well as to the staff and board of UAEM. Special thanks to Els Torreele PhD, Director of the Open Society Public Health Program’s Access to Essential Medicines Initiative, for her advice, support and encouragement. And thanks to the team at signals.ca for providing us with their design talent and enthusiastically agreeing to complete this project in record time! AUTHOR BIOGRAPHIES Rachel Kiddell-Monroe LL.M is a humanitarian, a lawyer and an activist. She is Special Adviser to Universities Allied for Essential Medicines (UAEM) and served 6 years as President of the UAEM board of directors. She is also a member of the International Board of directors for Médecins Sans Frontières/Doctors Without Borders (MSF). She lives in Montreal and has worked in south east Asia with human rights and environmental grassroots activists as well as with MSF in Djibouti, Rwanda, the Democratic Republic of Congo and throughout Latin America. Rachel has also served as the Canadian director of MSF’s Access to Medicines Campaign. Rachel sits on the board of UAEM Europe, on the Advisory Council of UAEM Brazil and the board of the Young Professionals for Chronic Disease Network. Rachel is a Professor of Practice at McGill University, lectures on international development and is part of the Adult Clinical Ethics Committee at McGill University Health Centres. She holds a Masters in Law and Bioethics from McGill. Alexandra Greenberg is a second year candidate for a Masters in International Health at the Johns Hopkins Bloomberg School of Public Health and is living in Lima, Peru conducting qualitative research on asthma care and treatment adherence as well as dengue vaccine introduction. She has been on the North American student coordinating committee of UAEM since September 2013 and worked as UAEM’s summer intern that same year. She led the North American Report Card project and was the researcher for UAEM’s map of alternative R&D initiatives. She has been the chapter president of UAEM at Johns Hopkins since September 2014. Merith Basey MSC has over a decade of experience in global public health, advocacy and project management. Following her postgraduate studies on Latin America, the UK native spent many years leading AYUDA, where she was responsible for fostering new partnerships, growing youth-led programs and strengthening local capacity in type 1 diabetes communities across Latin America and the Caribbean. After a Master’s degree at the London School of Hygiene and Tropical Medicine, she worked with the World AIDS Campaign in Amsterdam and went on to co-found the 100 Campaign. She is based in Washington, DC. TABLE OF CONTENTS Important User Notes ...................................................................... 1 Rationale......................................................................................... 3 Methodology ................................................................................... 5 Limitations of the Mapping ............................................................. 10 Executive Summary ....................................................................... 11 Mapping A Existing Initiatives .................................................................. 18 1. Drug discovery and data-sharing platforms......................... 19 2. Drug discovery incentives a. Prizes ........................................................................... 35 b. Tax subsidy/priority review incentives ............................. 39 c. Innovation fund/platform ............................................... 49 d. Venture philanthropy for drug discovery and development .......................................................... 60 3. Drug Licensing: Drug patent pools and related initiatives .... 65 4. Drug Advancement: Larger PPPs or organizations that house multiple innovative R&D initiatives ........................... 70 5. Drug development a. Disease-specific Product Development Partnerships challenging current R&D system ................................... 91 b. Product Development Partnerships working across diseases ..................................................................... 102 B Proposed Initiatives ............................................................. 118 1. Drug discovery and data-sharing platforms....................... 122 2. Drug discovery incentives ................................................ 125 a. Prizes ......................................................................... 125 b. Tax subsidy/priority review vouchers ............................ 130 c. Innovation fund/platform ............................................. 134 3. Drug Licensing: Drug patent pools and related initiatives .. 148 4. Drug Development a. Disease-specific Product Development Partnerships challenging current R&D system ................................ 149 b. Product Development Partnerships working across diseases ..................................................................... 152 5. Initiatives addressing 4 or more innovative R&D mechanisms ........................................... 154 Acronyms .................................................................................... 165 Glossary ...................................................................................... 168 Bibliography ................................................................................ 172 Appendix 1 ................................................................................. 194 RE:ROUTE • 1 TABLE OF CONTENTS 01 IMPORTANT USER NOTES We have an historic opportunity to take the long-running debate on transforming biomedical R&D to a new level. Today, millions of people globally fall between the ever-widening cracks in access to medicines. At the same time, outrage in rich countries over drug prices charged by pharmaceutical companies grows and our publicly funded healthcare budgets balloon to bursting point. Therefore, despite the limits to this mapping, which we readily acknowledge, we have decided to launch it now because we believe this is needed to support and inform the public and civil society debates taking place worldwide. Readers and users of this mapping should see this In the spirit of openness, transparency and mapping as the start of a process and not the end. collaboration, users of the mapping are invited to This mapping is not intended to be a comprehensive take an active part in developing this document review nor does it seek to make judgments on the with us so that it can evolve over time and remain merits of initiatives included. Rather it is intended current. We see this project as a continuously to give an overview of what is happening today in evolving contribution to the important dynamic response to the gaps left by the current biomedical gaining traction in the alternative biomedical R&D model. In this sense the initiatives included research and development (R&D) space. are referred to as alternative since they respond to a need in a different way from the current We invite and welcome your comments and biomedical R&D system and are based on different criticisms. As we launch this document, we accept goals. This mapping provides a short description that it is imperfect. Therefore, while maintaining of each initiative’s goals and principles. Beyond our methodology and criteria, we are expecting being a simple catalogue of initiatives, however, we to be challenged on the way we have categorized have sought to provide a new way to think and talk initiatives and for having missed information. about the different approaches aiming to promote We only ask that these challenges be based on and incentivize needs-driven R&D. We hope this information available in the public domain. mapping can provide a platform for discussion, collaboration and exchange to learn more about Any errors and/or misrepresentations are the sole what each of these initiatives have achieved, the responsibility of the authors. successes, the challenges and any lessons learnt. “We have known for years that we need to change how biomedical R&D is done. This report maps out 81 ways change is being made. While they may not set out a whole new system, they do represent important building blocks of a new approach to biomedical R&D where the needs of the people are put first.” Rachel Kiddell-Monroe, LL.M, Special Adviser, UAEM. RE:ROUTE • 3 TABLE OF CONTENTS 02 RATIONALE The inertia of the current R&D system in the face of recent, ongoing, and emerging global health crises is all too evident. The growing worldwide threat of antimicrobial innovation principles. On top of that, the landscape is resistance; the ongoing challenge of neglected changing so rapidly that the reports or articles that do diseases; and the tragic impacts of the 2014- exist are already out of date. 2015 Ebola epidemic all highlight the urgent need to ensure that affordable and appropriate In order to address this gap in the literature, medicines are available for all. These public health UAEM has created this mapping of alternative emergencies demonstrate yet again that we need R&D initiatives with support from the Open Society new and ethical ways to carry out biomedical Foundations. Based on a first review of over
Load more

Recommended publications
  • Second Quarter 2017
    Press release Second quarter 2017 Issued: Wednesday, 26 July 2017, London U.K. GSK delivers further progress in Q2 and sets out new priorities for the Group Q2 sales of £7.3 billion, +12% AER, +3% CER Total loss per share of 3.7p, +59% AER, +29% CER; Adjusted EPS of 27.2p, +12% AER, -2% CER Financial highlights • Pharmaceutical sales, £4.4 billion, +12% AER, +3% CER, Vaccines sales, £1.1 billion, +16% AER, +5% CER, Consumer Healthcare sales, £1.9 billion,+10% AER, flat at CER • Group operating margin 28.5%; Pharmaceuticals 33.6%; Vaccines 33.7%; Consumer 17.7% • Total Q2 loss per share of 3.7p reflecting charges resulting from increases in the valuation of Consumer and HIV businesses and new portfolio choices • Updated 2017 guidance: Adjusted EPS growth now expected to be 3% to 5% CER reflecting impact of Priority Review Voucher • H1 Free Cash Flow £0.4 billion (H1 2016: £0.1 billion) • 19p dividend declared for Q2; continue to expect 80p for FY 2017 Product and pipeline highlights • New product sales of £1.7 billion, +62% AER, +47% CER • HIV two drug regimen (dolutegravir and rilpivirine) filed for approval in US and EU • Shingrix filed for approval in Japan • FDA approval received for subcutaneous Benlysta for treatment of SLE New business priorities to 2020 • New priorities to strengthen innovation, improve performance and build trust • Pharmaceutical R&D pipeline reviewed with target over time to allocate 80% of capital to priority assets in two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation)
    [Show full text]
  • The Academy of Medical Sciences Review 2006 Fmedsci Contents
    The Academy of Medical Sciences Review 2006 FMedSci Contents 1 The Academy’s objectives and ambitions for medical science 2 A message from our President 4 Executive Director’s report 6 The strength of our Fellowship 8 How we work 10 Progress through partnership 12 Celebrating science 14 Advancing medical science and infl uencing policy 16 Building trust in science 18 Working in partnership with industry 20 The impact of research 22 Creating the next generation of medical scientists 24 Financial information 25 The Academy offi ce 14 16 18 20 22 The Academy’s objectives and ambitions for medical science The Academy of Medical Sciences promotes advances in medical science and campaigns to ensure these are converted as quickly as possible into healthcare benefi ts for society. Our 850 Fellows are the UK’s leading medical scientists from hospitals and general practice, academia, industry and the public service. Our Fellows are central to all we do. The excellence of their science, their contribution to medicine and society and the diversity of their achievements are refl ected throughout this review. The Academy seeks to play a pivotal role in determining the future of medical science in the UK, and the benefi ts that society will enjoy in years to come. We champion the UK’s strengths in medical science, including the unique opportunities for research aff orded by the NHS, encourage the implementation of new ideas and solutions – often through novel partnerships, promote careers and capacity building and help to remove barriers to progress. Throughout all our work the Academy strives to demonstrate our key attributes of excellence, independence, leadership, diversity and fl exibility.
    [Show full text]
  • Third Annual World Congress on the Insulin Resistance Syndrome Atherothrombotic Disease
    Reviews/Commentaries/Position Statements PERSPECTIVES ON THE NEWS Third Annual World Congress on the Insulin Resistance Syndrome Atherothrombotic disease ZACHARY T. BLOOMGARDEN, MD thalamic “clock,” which generates protein signals feeding back to create rhythmic behaviors and metabolic changes. Rhyth- his is the second of three articles re- structure, coagulation, and platelets in a mic mRNA expression of clock genes and viewing presentations at the 3rd An- prothrombotic direction (3). adipokines can also be demonstrated in T nual World Congress on the Insulin It is not apparent why insulin resis- mouse visceral adipose tissue, with adi- Resistance Syndrome, San Francisco, Cal- tance should be linked to atherosclerosis. ponectin and resistin responses both at- ifornia, 17–19 November 2005. The thrifty genotype hypothesis suggests tenuated in obese mice. Grant showed an that there is a survival advantage to insu- animal model in which pioglitazone im- proved hepatic rhythmicity. Thus, light, Diabetes and vascular disease lin resistance during periods of feast alter- as well as other stimuli such as ambient At a symposium cosponsored by the In- nating with famine (4), but that chronic ternational Society of Diabetes and Vascu- exposure to high nutrient intake converts temperature, acts via the suprachiasmatic lar Disease (www.dvdres.com), Peter the organism to the phenotype of insulin nucleus to send signals to adipocytes, the Grant (Leeds, U.K.) discussed the role of resistance sydrome and diabetes, with en- endothelium, liver, fibroblasts, cardiac insulin signaling pathways in acute coro- ergy preferentially stored in the liver and myocytes, and multiple other tissues, reg- nary syndrome (ACS), pointing out that in fat and with the clustering of risk mark- ulating reproductive, metabolic, and be- type 2 diabetes is characterized by fasting ers we have come to identify with insulin havioral aspects of life.
    [Show full text]
  • Jeremy Farrar
    FEATURE The BMJ THE BMJ INTERVIEW BMJ: first published as 10.1136/bmj.n459 on 19 February 2021. Downloaded from [email protected] Cite this as: BMJ 2021;372:n459 http://dx.doi.org/10.1136/bmj.n459 Jeremy Farrar: Make vaccine available to other countries as soon as Published: 19 February 2021 our most vulnerable people have received it The SAGE adviser and Wellcome Trust director tells Mun-Keat Looi how the UK government acted too slowly against the pandemic, about the perils of vaccine nationalism, and why he is bullish about controlling covid variants Mun-Keat Looi international features editor “Once the UK has vaccinated our most vulnerable among healthcare workers. We had no human communities and healthcare workers we should make immunity, no diagnostics, no treatment, and no vaccines available to other countries,” insists the vaccines. infectious disease expert Jeremy Farrar. This could Every country should have acted then. Singapore, avert further public health and economic disaster, China, and South Korea did. Yet most of Europe and he says, describing it as “enlightened self-interest, North America waited until the middle of March, and as well as the right ethical thing to do.” that defined the first wave. Countries including the In April 2020, soon after the first UK lockdown began, UK were unwilling to act early, before they felt Farrar predicted that the UK would have one of the comfortable; were unwilling to go deeper than they worst covid-19 death rates in Europe. As a member thought they had to; and were unwilling to keep of the Scientific Advisory Group for Emergencies restrictions in place for as long as was needed.
    [Show full text]
  • Connecting Immunology
    CONNECTING IMMUNOLOGY IN THE TIME OF COVID-19 BSI VIRTUAL CONFERENCE 1-2 DECEMBER 2020 CONNECTINGLOGY NO VID-19 MU OF CO IM TIME IN THE CONNECTING CONNECTING IMMUNOLOGY IN THE TIME OF COVID-19 2 IMMUNOLOGY IN THE TIME OF COVID-19 Welcome On behalf of the BSI’s Congress Committee, I would like to welcome you all to the British Society for Immunology’s virtual conference ‘Connecting immunology in the time of COVID-19’. This is the BSI’s first ever virtual conference at this scale and our committee have worked hard to develop a diverse programme of plenary and parallel sessions covering many of the hot topics within immunology, which we hope will appeal to delegates. With our cutting-edge two-day agenda coupled with our interactive online platform, we aim to bring together immunologists from the UK and worldwide, providing attendees with the latest research developments from Gary Entrican internationally acclaimed leaders in their field. We’re honoured to welcome a number of high-profile speakers including our two keynote presenters from the US, Garry Nolan and Akiko Iwasaki. Additionally, we are privileged to be joined by Sir Patrick Vallance, the Chief Scientific Adviser to the UK Government, who will speak in our COVID-19 themed plenary session alongside Paul Moss, the lead for the UK Coronavirus Immunology Consortium. Among the many other highlights of our programme, I would particularly recommend you attend our Bright Sparks sessions on the first morning, featuring ground-breaking work from promising early career researchers. Additionally, our Coronavirus Panel Discussion on the second afternoon promises to be a fascinating exchange of views on how immunology has fed into the pandemic response.
    [Show full text]
  • Primary Amoebic Meningoencephalitis Amoebic Meningoencephalitis Is Primary Ś
    PØEHLEDOVÉ PRÁCE PØEHLEDOVÉ JE NEGLERIÓZA VEREJNO-ZDRAVOTNÍCKYM PROBLÉMOM? IS PRIMARY AMOEBIC MENINGOENCEPHALITIS (NAEGLERIASIS) A PUBLIC HEALTH PROBLEM? KATARÍNA TRNKOVÁ, LUCIA MAĎAROVÁ, CYRIL KLEMENT Regionálny úrad verejného zdravotníctva so sídlom v Banskej Bystrici, odbor lekárskej mikrobiológie SOUHRN Neglerióza alebo primárna amébová meningoencefalitída (PAM) je zriedkavé ochorenie CNS, pôvodcom ktorého je vo¾ne žijúca meòavka Naegleria fowleri. Medzi stovkami vo¾ne žijúcich meòaviek sú známe i ïalšie rody, ktorých zástupcovia sú schopní infikovaś èloveka a vyvolaś u neho ochorenie. Za patogény sú považovaní zástupcovia rodov Acanthamoeba a Naegleria a druhy Balamuthia mandrillaris a Sappi- nia diploidea. Infekcie spôsobené týmito organizmami vyvolávajú u ¾udí syndrómy v rozsahu od akútnych fatálnych ochorení po chronické, tkanivá napadajúce infekcie s granulomatóznymi prejavmi. Epidemiológia, imunológia, patológia a klinické prejavy týchto infekcií sa vzájomne ve¾mi líšia. Príspevok podáva preh¾ad o pôvodcovi ochorenia PAM, o jeho morfológii, životnom cykle, ekológii ako aj o patogenéze, symptomatike a spôsoboch laboratórnej diagnostiky negleriózy. K¾úèové slová: neglerióza, primárna amébová meningoencefalitída, epidemiológia, laboratórna diagnostika Naegleria fowleri SUMMARY Naegleriasis or primary amoebic meningoencephalitis (PAM) is invariably an acute, often fulminant infection of CNS caused by Naegleria fowleri, a small, free-living amoeba. Pathogenic free-living amoebae can cause serious illnesses in humans. The amoe- HYGIENA bae belonging to the genus Naegleria, Acanthamoeba and Balamuthia mandrillaris and Sappinia diploidea produce syndromes in man ranging from acute fatal disease to chronic tissue invasion with granulomatous manifestation. The purpose of this report is to describe the clinical history, treatment, pathology and methods of laboratory diagnostic of naegleriasis. Key words: primary amoebic meningoencephalitis, naegleriasis, epidemiology, laboratory diagnostics of Naegleria fowleri ÈÍSLO 2 Úvod Obr.
    [Show full text]
  • SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1
    The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis,
    [Show full text]
  • Financing Vaccines for Global Health Security
    NBER WORKING PAPER SERIES FINANCING VACCINES FOR GLOBAL HEALTH SECURITY Jonathan T. Vu Benjamin K. Kaplan Shomesh Chaudhuri Monique K. Mansoura Andrew W. Lo Working Paper 27212 http://www.nber.org/papers/w27212 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 May 2020 We thank Ellen Carlin, Doug Criscitello, Margaret Crotty, Narges Dorratoltaj, Per Etholm, Jeremy Farrar, Nimah Farzan, Mark Feinberg, Jose-Maria Fernandez, John Grabenstein, Peter Hale, Richard Hatchett, Peter Hotez, Daniel Kaniewski, Adel Mahmoud, Mike Osterholm, May 2020 Farrar, Nimah Kevin Outterson, Chi Heem Wong, CEPI leadership, and two reviewers and the editor for helpful comments and discussion, and Jayna Cummings for editorial assistance. Research support from the MIT Laboratory for Financial Engineering and the Warren Alpert Medical School of Brown University is gratefully acknowledged. The views and opinions expressed in this article are those of the authors only, and do not necessarily represent the views and opinions of any institution or agency, any of their affiliates or employees, any of the individuals acknowledged above, or the National Bureau of Economic Research. Funding support from the MIT Laboratory for Financial Engineering is gratefully acknowledged, but no direct funding was received for this study and no funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript). At least one co-author has disclosed a financial relationship of potential relevance for this research.
    [Show full text]
  • Oxford Medicine
    Oxford Medicine THE NEWSLETTER OF THE OXFORD MEDICAL ALUMNI OXFORD MEDICINE • DECEMBER 2019 Courtesy of Ludwig Cancer Research of Ludwig Cancer Courtesy The Regius Professor Sir Tingewick is Does reflects on Peter Ratcliffe 80! Developmental 45 years in FRS, Nobel Dyslexia Really medicine Laureate Exist? 2 / OXFORD MEDICINE DECEMBER 2019 President’s Piece Welcome to the December Sir William Osler’s Centenary commemorations will issue of Oxford Medicine, the continue throughout the year in Oxford and beyond. newsletter for Oxford Medical The Osler Club is the first of a number of thriving Alumni (OMA) who have postgraduate Oxford medical societies we plan to feature. trained, taught, or worked at Professor Terence Ryan summarises this year’s five Osler Oxford. Professor John Morris, Club seminars exploring the Oslerian theme ‘For Health OMA president for the past and Wellbeing, Science and Humanities are one’. six years, handed the baton Tingewick is 80 this year. In 2019, as in 1939, Tingewick to me in September. It is a Dr Lyn Williamson, is still the most inclusive Oxford clinical student society. OMA President daunting task to take over from This year, every first year clinical student took part - someone so beloved and so that is 165! The show was a triumph of teamwork and respected, who has taught anatomy to generations talent. The legacy of camaraderie will last a lifetime - as of Oxford students and postgraduates, and shaped witnessed by the 80th anniversary celebrations. Dr Derek the preclinical school for many years. With his Roskell, Senior Tingewick Member for 25 years adds his characteristic kindness and wisdom, he said: ‘You will be fine - and I will be there to advise you’.
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Issues of the Presence of Parasitic Protozoa in Surface Waters
    E3S Web of Conferences 30, 01010 (2018) https://doi.org/10.1051/e3sconf/20183001010 Water, Wastewater and Energy in Smart Cities Issues of the presence of parasitic protozoa in surface waters Eliza Hawrylik1* 1 Department of Chemistry, Biology and Biotechnology, Faculty of Civil and Environmental Engineering, Bialystok University of Technology, Wiejska 45E Street, 15-351 Bialystok, Poland Abstract. Parasitic protozoa are very numerous organisms in the environment that play an important role in the spread of water-borne diseases. Water-borne epidemics caused by parasitic protozoa are noted throughout the world. Within these organisms, intestinal protozoa of the genera Cryptosporidium and Giardia are ones of the most serious health hazards for humans. This paper focuses on the problem of the presence of parasitic protozoa in surface waters. Characteristics of the most frequently recognized pathogens responsible for water-borne outbreaks were described, as well as sources of contamination and surface waters contamination due to protozoa of the genus Cryptosporidium and Giardia were presented. The methods of destroying the cysts and oocysts of parasitic protozoa used nowadays in the world were also presented in a review. 1 Occurrence of parasitic protozoa in surface water Parasitic protozoa are unicellular animal organisms that are very numerously isolated from natural waters, soils, food and media contaminated with animal manure and diseased humans. They are cosmopolitans, and are found in all countries of the world. They play an important role in the spread of water-borne diseases [1,2]. Water is the most common source of infection with protozoa, such as Entamoeba histolytica, Giardia intestinalis, Cryptosporidium sp., Cyclospora cayetanensis, Toxoplasma gondii.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]